Résumé
Unfortunately, safety and efficacy data on these new treatments in people over 65 are scarce. Objectives: the objectives were weight loss after one year of treatment with semaglutide 2.4 mg/week, lean mass loss after six months of treatment, and evaluation of adverse events during treatment. Methods: the patients were adults with grade 3 obesity (BMI > 40 kg/m²) with at least one comorbidity, treated with semaglutide as part of the early access protocol between April 2022 and April 2023 at Montpellier University Hospital. Body composition was assessed at baseline and after six months of treatment. Biological data were collected at baseline and during treatment. We performed various comparative analyses based on age. Results: a total of 386 patients were treated with semaglutide 2.4 mg. Weight loss after one year was 13.1% (SD 6.3; p=0.4) in subjects over 65 years old compared to 14.7% (SD 7.6; p=0.4) in those under 65. In those over 65, weight loss after one year was greater in people over 70 compared to those under 70 (166% (SD 53) vs 106% (SD 61), p=0.026). Lean mass loss was 4.2% (11.8; p=0.5) in those under 65 and 8.8% (14.8; p=0.5) in those over 65. 57.5% of patients experienced adverse events. Those under 65 had more nausea (35.2% vs. 11%, p=0.02). Conclusion: our study showed significant weight loss, comparable between the <65 years and ≥65 years age groups. The frequency of adverse events and changes in fat mass did not differ based on age.